Casi soars on positive early-stage data for blood cancer therapy

CASI Pharmaceuticals

05/03/2024 12:36

** Shares of Casi Pharmaceuticals  CASI.O  rise ~43.6% to
$7.26 premarket
    ** Co says its combination therapy for patients with
indolent Non-Hodgkin's Lymphoma (iNHL) showed encouraging 
efficacy data   
    ** The study resulted in 4 partial responses and 1 complete
response out of 8 evaluable patients
    ** A partial response is at least 30% decrease in cancer and
a complete response is the disappearance of all signs of cancer 
    ** iNHL is a disease in which cancer cells grow and spread
slowly in the lymph system
    ** Up to last close, stock has more than doubled in the last
12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))